Analysts forecast that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report ($0.06) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). Catalyst Pharmaceuticals posted earnings per share of ($0.05) in the same quarter last year, which suggests a negative year-over-year growth rate of 20%. The business is expected to issue its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.20). For the next year, analysts expect that the firm will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.45) to ($0.13). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Catalyst Pharmaceuticals.
A number of equities research analysts have weighed in on CPRX shares. Zacks Investment Research lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 10th. Roth Capital set a $5.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 1st. Piper Jaffray Companies set a $8.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 1st. Finally, SunTrust Banks set a $5.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $6.25.
Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) traded up $0.07 during midday trading on Wednesday, reaching $3.99. The company’s stock had a trading volume of 713,507 shares, compared to its average volume of 1,610,000. Catalyst Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $4.51. The firm has a market cap of $343.32, a price-to-earnings ratio of -19.00 and a beta of 1.68.
A number of hedge funds and other institutional investors have recently modified their holdings of CPRX. Schwab Charles Investment Management Inc. acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $333,000. Rhumbline Advisers acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $209,000. State of Wisconsin Investment Board acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $149,000. Bank of New York Mellon Corp grew its stake in Catalyst Pharmaceuticals by 206.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 211,979 shares of the biopharmaceutical company’s stock valued at $585,000 after purchasing an additional 142,803 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Catalyst Pharmaceuticals by 1,833.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,536,300 shares of the biopharmaceutical company’s stock worth $4,240,000 after acquiring an additional 1,456,830 shares in the last quarter. Hedge funds and other institutional investors own 34.75% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.